Zacks Investment Research on MSN
TGTX completes enrollment in Phase III study on subcutaneous Briumvi
TG Therapeutics TGTX announced that it has completed enrollment in the phase III study evaluating the subcutaneous ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...
Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with ...
NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), ...
--TG Therapeutics, Inc., announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI, the company’ s anti-CD20 monoclonal antibody, in people with relapsing forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results